Literature DB >> 12767721

Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain.

Kenneth Maiese1, Zhao Zhong Chong.   

Abstract

Although usually identified as an essential cellular nutrient for cellular growth and maintenance, nicotinamide is under development as a novel cytoprotectant for acute and chronic neurodegenerative disorders. Here, we outline support for the premise that nicotinamide both prevents and reverses neuronal and vascular cell injury. Nicotinamide fosters DNA integrity and maintains phosphatidylserine membrane asymmetry to prevent cellular inflammation, cellular phagocytosis and vascular thrombosis. The downstream cellular and molecular cascades are considered vital for the cytoprotection offered by nicotinamide. These pathways encompass the modulation of Akt, the forkhead transcription factor FKHRL1, mitochondrial membrane potential, caspase activities and cellular energy metabolism, but remain independent of intracellular pH and mitogen-activated protein kinases. As both a therapeutic agent and an investigational tool, nicotinamide offers new therapeutic strategies for degenerative disorders of the CNS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767721     DOI: 10.1016/S0165-6147(03)00078-6

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  75 in total

Review 1.  Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system.

Authors:  Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2004-04       Impact factor: 2.303

2.  Protective function of nicotinamide against ketamine-induced apoptotic neurodegeneration in the infant rat brain.

Authors:  Najeeb Ullah; Ikram Ullah; Hae Young Lee; Muhammad Imran Naseer; Park Moon Seok; Jawad Ahmed; Myeong Ok Kim
Journal:  J Mol Neurosci       Date:  2011-12-08       Impact factor: 3.444

Review 3.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

4.  Preclinical efficacy testing in middle-aged rats: nicotinamide, a novel neuroprotectant, demonstrates diminished preclinical efficacy after controlled cortical impact.

Authors:  Alicia A Swan; Rupa Chandrashekar; Jason Beare; Michael R Hoane
Journal:  J Neurotrauma       Date:  2011-01-09       Impact factor: 5.269

5.  NAD+ treatment induces delayed autophagy in Neuro2a cells partially by increasing oxidative stress.

Authors:  Jin Han; Shengtao Shi; Lan Min; Teresa Wu; Weiliang Xia; Weihai Ying
Journal:  Neurochem Res       Date:  2011-08-11       Impact factor: 3.996

Review 6.  Vitamins and nutrients as primary treatments in experimental brain injury: Clinical implications for nutraceutical therapies.

Authors:  Cole Vonder Haar; Todd C Peterson; Kris M Martens; Michael R Hoane
Journal:  Brain Res       Date:  2015-12-23       Impact factor: 3.252

Review 7.  Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury.

Authors:  Z Z Chong; F Li; K Maiese
Journal:  Histol Histopathol       Date:  2005-01       Impact factor: 2.303

Review 8.  Winding through the WNT pathway during cellular development and demise.

Authors:  F Li; Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2006-01       Impact factor: 2.303

Review 9.  Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

Review 10.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.